ALLO logo

Allogene Therapeutics, Inc.

ALLO
Healthcare|Biotechnology|US
$1.04
-0.05 (-4.59%)
Tangible Book / Share
$1.13
Cash / Share
$0.85
Next Earnings Report
Mar 11, 2027
EPS est. -$0.14 · Revenue est. $2.5K
Financing Filings (last 12 months)
4
Shelf registrations / offering prospectuses — latest Aug 12, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (4)

Dec 2027
Est. completion
P2Large B-cell Lymphoma
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273n=250
Feb 2028
Est. completion
P1Systemic Lupus Erythematosus (With and Without Nephritis)
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
NCT07085104n=66
Feb 2029
Est. completion
P1P2Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
NCT04416984n=160
Jan 2030
Est. completion
P1Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT04696731n=120

Recent Press Releases

Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
Nov 5, 2026 · GlobeNewsWire
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
Nov 3, 2026 · GlobeNewsWire
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
Oct 29, 2026 · GlobeNewsWire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Oct 26, 2026 · GlobeNewsWire
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
Sep 2, 2026 · GlobeNewsWire
Allogene Therapeutics Announces Participation in September Investor Conference
Aug 31, 2026 · GlobeNewsWire
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Aug 12, 2026 · GlobeNewsWire

SEC Filings (73)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 202610-QQuarterly reportDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Oct 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Sep 30, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Sep 2, 20268-KMaterial eventDocumentIndex
Aug 20, 2026EFFECTDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 12, 2026S-3Shelf registrationDocumentIndex
Aug 12, 202610-QQuarterly reportDocumentIndex
Aug 12, 20268-KMaterial eventDocumentIndex
Aug 7, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 7, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jun 22, 20268-KMaterial eventDocumentIndex
Jun 22, 2026424B5Offering prospectusDocumentIndex
May 28, 2026DEFA14AProxy / shareholder voteDocumentIndex
May 28, 20268-KMaterial eventDocumentIndex
May 21, 2026DEFA14AProxy / shareholder voteDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 13, 202610-QQuarterly reportDocumentIndex
May 13, 20268-KMaterial eventDocumentIndex
Apr 30, 2026ARSAnnual report to holdersDocumentIndex
Apr 30, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 30, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 23, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 20, 2026PRE 14AProxy / shareholder voteDocumentIndex
Apr 15, 20268-KMaterial eventDocumentIndex
Apr 15, 2026424B5Offering prospectusDocumentIndex
Apr 13, 2026424B5Offering prospectusDocumentIndex
Apr 13, 20268-KMaterial eventDocumentIndex
Apr 13, 20268-KMaterial eventDocumentIndex
Mar 12, 2026S-8Employee stock planDocumentIndex
Mar 12, 202610-KAnnual reportDocumentIndex
Mar 12, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Feb 13, 2026SC 13GPassive 5%+ stakeDocumentIndex
Nov 13, 2025SC 13G/APassive 5%+ stakeDocumentIndex